Literature DB >> 8486791

Protamine and protamine-insulins exacerbate the vascular response to injury.

E R Edelman1, L A Pukac, M J Karnovsky.   

Abstract

Endothelial cells and smooth muscle cells produce heparinlike compounds that are growth inhibitory for vascular smooth muscle cells, and it has been suggested that these compounds play a regulatory role that is perturbed with vascular injury. Indeed, exogenous heparin preparations effectively suppress smooth muscle cell proliferation following injury imposed on vascular endothelium. We now report that protamine, an agent that binds heparin and negates its anticoagulant properties, has potent stimulatory effects on vascular smooth muscle cell proliferation. The administration of protamine, alone or as part of commonly used insulin preparations, stimulated the proliferation of cultured smooth muscle cells, exacerbated vascular smooth muscle cell proliferative lesions in laboratory rats, and interfered with the growth-inhibitory effects of heparin in culture and in vivo. These results confirm the importance of endogenous heparinlike compounds in arterial homeostasis and may require reconsideration of protamine use following vascular reparative procedures and in diabetics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486791      PMCID: PMC288236          DOI: 10.1172/JCI116460

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Quantitative in-vivo studies on angiogenesis in a rat sponge model.

Authors:  S P Andrade; T P Fan; G P Lewis
Journal:  Br J Exp Pathol       Date:  1987-12

2.  Comparative neutralization of lung- and mucosal-derived heparin by protamine sulfate using in vitro and in vivo methods.

Authors:  L R Lowary; F A Smith; E Coyne; N W Dunham
Journal:  J Pharm Sci       Date:  1971-04       Impact factor: 3.534

3.  Circulating IgG antibody to protamine in patients treated with protamine-insulins.

Authors:  A B Kurtz; R S Gray; S Markanday; J D Nabarro
Journal:  Diabetologia       Date:  1983-10       Impact factor: 10.122

4.  Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin.

Authors:  J R Guyton; R D Rosenberg; A W Clowes; M J Karnovsky
Journal:  Circ Res       Date:  1980-05       Impact factor: 17.367

5.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

6.  Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.

Authors:  A Strasser; S Whittingham; D L Vaux; M L Bath; J M Adams; S Cory; A W Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

7.  Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury.

Authors:  E R Edelman; D H Adams; M J Karnovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.

Authors:  M Bar-Ner; A Eldor; L Wasserman; Y Matzner; I R Cohen; Z Fuks; I Vlodavsky
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

Review 9.  Serious adverse reactions to protamine sulfate: are alternatives needed?

Authors:  J M Weiler; P Freiman; M D Sharath; W J Metzger; J M Smith; H B Richerson; Z K Ballas; P C Halverson; D J Shulan; S Matsuo
Journal:  J Allergy Clin Immunol       Date:  1985-02       Impact factor: 10.793

10.  Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group.

Authors:  J J Castellot; J Choay; J C Lormeau; M Petitou; E Sache; M J Karnovsky
Journal:  J Cell Biol       Date:  1986-05       Impact factor: 10.539

View more
  4 in total

1.  Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo.

Authors:  M A Lovich; E R Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Tissue engineered perivascular endothelial cell implants regulate vascular injury.

Authors:  A Nathan; M A Nugent; E R Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

3.  CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury.

Authors:  W W Hancock; D H Adams; L R Wyner; M H Sayegh; M J Karnovsky
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

4.  Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model.

Authors:  M Simons; E R Edelman; R D Rosenberg
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.